Journal Article10.1200/JCO.2005.12.516
Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia
William G. Wierda,Susan O'Brien,Sijin Wen,Stefan Faderl,Guillermo Garcia-Manero,Deborah A. Thomas,Kim Anh Do,Jorge E. Cortes,Charles Koller,Miloslav Beran,Alessandra Ferrajoli,Francis J. Giles,Susan Lerner,Maher Albitar,Hagop M. Kantarjian,Michael J. Keating +15 more
TL;DR: FCR induced the highest CR rate reported in a clinical trial of previously treated patients with CLL, and molecular remissions were achieved in a third of patients achieving CR.
read more
Abstract: Purpose The efficacy, toxicity, and tolerability of chemoimmunotherapy with the combination of fludarabine, cyclophosphamide, and rituximab (FCR) were evaluated in previously treated patients with chronic lymphocytic leukemia (CLL). The purpose of this study was to improve the complete remission (CR) rate for previously treated patients and evaluate the quality of bone marrow response. Patients and Methods One hundred seventy-seven previously treated patients with CLL were evaluated. Treatment consisted of rituximab 375 mg/m2 day 1 of course 1 and 500 mg/m2 day 1 of courses 2 to 6; fludarabine 25 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6; and cyclophosphamide 250 mg/m2/d days 2 to 4 of course 1 and days 1 to 3 of courses 2 to 6. Courses were repeated every 4 weeks. Results CR was achieved in 25% of 177 patients, and nodular partial remission and partial remission were achieved in 16% and 32% of patients, respectively; the overall response rate was 73%. Twelve (32%) of 37 complete r...
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Second line treatment for relapsed chronic lymphocytic leukemia
Giuseppe Rossi
- 16 Jun 2009
TL;DR: In spite of the remarkable therapeutic achievements obtained with purine analogues and monoclonal antibodies, chronic lymphatic leukaemia (CLL) has still to be considered an incurable disease.
1
First-line therapy of chronic lymphocytic leukemia: when and how to treat
Ester M. Orlandi
- 16 Jun 2009
TL;DR: In the last decade, impressive progress has been achieved in biological characterization of CLL, allowing better understanding of the pathophysiology of the disease and identification of biological features relevant to prognostic stratification.
1
•Dissertation
Estudi del fenomen de la transformació histològica en síndromes limfoproliferatives indolents
Eva Giné Soca
- 08 Jun 2010
TL;DR: Aixi mateix et al. as mentioned in this paper presented a series of patients of the Clinic de Barcelona, 276 patients and 614 cases of the leucemia limfatica cronica (LLC).
Critical appraisal of the role of rituximab in the treatment of patients with previously untreated or treated chronic lymphocytic leukemia (CLL).
TL;DR: The addition of rituximab to chemotherapy boosted overall response rates, complete response rates and prolonged progression free survival, and recent data showed an overall survival benefit with FCR.
References
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.
Richard Peto,M.C. Pike,P. Armitage,N. E. Breslow,David Cox,S V Howard,N Mantel,Klim McPherson,Julian Peto,Pete Smith +9 more
TL;DR: Efficient methods of analysis of randomized clinical trials in which the authors wish to compare the duration of survival among different groups of patients are described.
8.7K
•Journal Article
Inhibition of Interleukin 10 by Rituximab Results in Down-Regulation of Bcl-2 and Sensitization of B-cell Non-Hodgkin’s Lymphoma to Apoptosis
TL;DR: It is demonstrated that one mechanism by which Rituximab sensitizes NHL to chemotherapeutic drugs is mediated through down-regulation of antiapoptotic IL-10 autocrine/paracrine loops and Bcl-2.
317
Results of Fludarabine and Prednisone Therapy in 264 Patients With Chronic Lymphocytic Leukemia With Multivariate Analysis-Derived Prognostic Model for Response to Treatment
Susan O'Brien,Hagop M. Kantarjian,Miloslav Beran,Terry K. Smith,Charles Koller,Elihu H. Estey,L. E. Robertson,Susan Lerner,Michael J. Keating +8 more
TL;DR: Logistic regression analysis selected 4 factors to be significantly associated with worse response: Rai III-IV stage disease, prior therapy, older age, and low albumin levels to derive a probability of response based on the regression equation.
300